CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...
Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
News-Medical.Net on MSN
Timing of genetic mutation dictates childhood leukemia aggressiveness
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...
The genetically engineered food is also protein packed and sustainable, say scientists. Chinese researchers used gene-editing ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
Irish Independent on MSN
Innovative therapy gives hope to patients whose blood cancer ‘seemed incurable’
Almost two thirds of patients with T-cell acute lymphoblastic leukaemia involved in a clinical trial of the treatment are now ...
A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.
A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street ...
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results